4M Therapeutics Inc.: Funding, Investors & Team (Oct 2026)
4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer’s disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.
4M Therapeutics Inc. has raised $120k across 2 funding rounds on record, the most recent a Seed announced in Aug 2025.
4M Therapeutics Inc. Company Profile and Key Stats
Latest funding round on record: Aug 2025.
4M Therapeutics Inc. Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
4M Therapeutics Inc. raised $120k in an undisclosed round announced in Nov 2024.
9 months later, a Seed was announced in Aug 2025 with no disclosed amount.
4M Therapeutics Inc. Founders and Leadership Team
Contact details for the 4M Therapeutics Inc. team: 1 of 2 have an email address on file.
Start 14-day free trial →4M Therapeutics Inc. Funding Compared to Other Biotechnology Startups
Funded Startups Like 4M Therapeutics Inc. in Biotechnology and Princeton
Companies Similar to 4M Therapeutics Inc.
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
4M Therapeutics Inc. Funding FAQs
What does 4M Therapeutics Inc. do?
4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer’s disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.
How much funding has 4M Therapeutics Inc. raised?
4M Therapeutics Inc. has raised $120k across 2 rounds on record.
When did 4M Therapeutics Inc. last raise funding?
4M Therapeutics Inc.'s most recent funding round on record was announced in Aug 2025. The amount was not disclosed.
Who founded 4M Therapeutics Inc.?
FundedIQ lists Ben Williams (Founder), Pablo Lapuerta (Founder) at 4M Therapeutics Inc..
Where is 4M Therapeutics Inc. headquartered?
4M Therapeutics Inc. is based in Princeton, New Jersey, United States.
How many employees does 4M Therapeutics Inc. have?
4M Therapeutics Inc. is in the 1-10 employee band.
About FundedIQ's 4M Therapeutics Inc. Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for 4M Therapeutics Inc. is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.